Skip to main content
. 2021 Sep 9;480(2):359–368. doi: 10.1007/s00428-021-03202-6

Table.1.

Origin and prevalence of primary and metastatic neuroendocrine tumors G3

Total NEN
N (%)
NET G3
N
%
Total number of NEN
%
Total number of NET G3
Total N [%] 1513 (100) 130 9 100
     Primary 1024 (68) 40 4 31
     Metastasis 489 (32) 90 18 69
Pancreas 418 (28)  54 13 42
     Primary 279 (67) 16 6 30
     Metastasis 135 (33) 38 28 70
Stomach 174 (12) 10 6 8
     Primary 165 (95) 7 4 70
     Metastasis 9 (5) 3 33 30
Duodnum/PoV 108 (7) 2 2 2
     Primary 97 (90) 2 3 100
     Metastasis 11 (10) 0 0 0
Ileum 158 (10) 7 4 5
     Primary 102 (65) 1 1 14
     Metastasis 56 (35) 6 11 86
Appendix 79 (5) 0 0 0
     Primary 77 (100) 0 0 0
     Metastasis 0 (0) 0 0 0
Colon 82 (5) 1 1 1
     Primary 75 (91) 1 1 100
     Metastasis 7 (9) 0 0 0
Rectum 71 (5) 4 6 3
     Primary 64 (90) 3 5 75
     Metastasis 7 (10) 1 14 25
Lung 170 (11) 26 15 20
     Primary 87 (51) 9 10 35
     Metastasis 81 (49) 17 21 65
Other sites 101 (6)a 3c 3 2
     Primary 76 (75) 1 1 33
     Metastasis 25 (26) 2 8 67
Unknown 152 (10)b 23 15 18

Abbreviations: NET neuroendocrine tumor, PoV papilla of Vater. aIincluding 5 esophagus, 12 biliary system, 2 liver, 4 kidney, 17 urinary tract, 15 prostate, 10 uterus, 8 ovary, 1 vagina, 9 breast, 3 presacral, 13 head and neck; bAll cases examined in metastatic site, c1 prostate, 1 breast, 1 presacral